Camp Arifjan marks 30 years since Gulf War, with 25%-33% illness signal for UAE clinics

Camp Arifjan in Kuwait marked 30 years since the First Gulf War victory at a 10 March 2021 ceremony, a reminder for UAE clinics and pharmacies that Gulf War exposure histories still affect medication use, claims review and chronic-care pathways.

The story is military commemoration, rather than a UAE outbreak alert. The operating issue for Dubai clinics is practical: patients who served, contracted, or lived near Gulf War theatres may present decades later with chronic fatigue, pain, respiratory complaints, gastrointestinal symptoms, sleep disorders or mental health needs. In Dubai, the relevant regulator is the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain it is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah it is the Ministry of Health and Prevention (MOHAP).

What happened at Camp Arifjan

The U.S. Army Reserve report, published on 15 March 2021, said six Army Reserve soldiers deployed with the 310th Sustainment Command (Expeditionary) shared memories of First Gulf War service as U.S. and Kuwaiti military leaders marked Kuwait's liberation.

The ceremony followed the historical sequence familiar to Gulf-based operators. Operation Desert Shield ran from 2 August 1990 to 17 February 1991. Operation Desert Storm ran from 17 February 1991 to 28 February 1991. The formal armistice was signed on 11 April 1991.

I still remember Operation Desert Storm.

Brig. Gen. Mohammad Al Dhafiri, Kuwaiti Army Land Forces Commander

The report named Maj. Gen. Patrick Hamilton, commanding officer of the 36th Infantry Division and Task Force Spartan, as the U.S. commander who addressed the event. It also named Army Reserve personnel including Chief Warrant Officer 4 Denrick Mills, who served in Riyadh during the 1990-91 deployment and was back in Kuwait with the 310th ESC in 2021.

Why UAE providers should care

The U.S. Department of Veterans Affairs says between 25% and 33% of Gulf War veterans have some degree of medically unexplained chronic symptoms, often described as chronic multisymptom illness or Gulf War illness. That number does not create a UAE prevalence estimate. It does give UAE providers a defensible reason to ask older U.S., British, Kuwaiti and other coalition-linked patients about deployment history when symptoms persist for six months or more.

For pharmacy operators, the risk is fragmentation. A patient with pain, sleep disturbance, gastrointestinal symptoms and anxiety can collect medicines across multiple prescribers unless medication reconciliation is built into intake and refill workflows. DHA-licensed pharmacies in Dubai should document active medicines, controlled or semi-controlled medicine status where relevant, and prescriber details. DOH and MOHAP facilities should apply the same discipline through their own licensing and medicine-control channels.

• COOs: add military or conflict-zone exposure questions to intake forms for persistent multisystem complaints.
• CFOs: check whether plans require pre-authorisation for long-term pain, sleep, gastroenterology, psychiatry or rehabilitation claims.
• Medical directors: set referral triggers for unexplained symptoms lasting six months or more.
• Pharmacy heads: require medication reconciliation before repeated refills for sedatives, opioids, neuropathic pain medicines or overlapping gastrointestinal drugs.

Coverage and patient pathway in the UAE

Insurers should treat this as a claims-quality issue. Daman and Thiqa are especially relevant in Abu Dhabi, while Sukoon is one of the commercial insurers seen across UAE provider networks. Coverage depends on the member's policy, network tier, diagnosis coding, referral rules and pre-authorisation requirements. Operators should direct patients to their insurer's schedule of benefits rather than quote informal prices.

Where patients pay directly, providers should publish consultation and pharmacy prices at the point of care or give a written estimate before dispensing. If a clinic cannot confirm a price, the patient should ask for the regulator licence number, the prescriber's licence status and the insurer network status before treatment. DHA's Sheryan and Dubai Medical Registry, DOH's lists and tools, and MOHAP's medical facilities directory are the official routes for checking licensed facilities.

The immediate action is modest. Dubai clinics should update intake forms, Abu Dhabi providers should align referral and pre-authorisation workflows, and northern emirates pharmacies should verify MOHAP licensing and medicine-control requirements before positioning chronic symptom support services. Patients looking for licensed pharmacy providers can start with the UAE Open Healthcare Directory, which lists DHA, DOH and MOHAP-registered providers across the UAE.